This is a haemophilia news story, published by Yahoo Finance, that relates primarily to Dupixent news.
For more haemophilia news, you can click here:
more haemophilia newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
blockbuster asthma drug Dupixent. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Dupixent news, French drugmaker news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Sanofi partnersReuters
•78% Informative
Sales of Dupixent , approved to treat conditions such as asthma and eczema, rose 29.2% to 3.30 billion euros .
French drugmaker now forecasts stable earnings per share 2024 business.
New launches include haemophilia treatment Altuviiio , Beyfortus and type 1 diabetes treatment Tzield .
VR Score
89
Informative language
98
Neutral language
11
Article tone
semi-formal
Language
English
Language complexity
59
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links